These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 15672299

  • 1. Photodynamic therapy with verteporfin for choroidal neovascularisations in clinical routine outside the TAP study. One- and two-year results including juxtafoveal and extrafoveal CNV.
    Wachtlin J, Stroux A, Wehner A, Heimann H, Foerster MH.
    Graefes Arch Clin Exp Ophthalmol; 2005 May; 243(5):438-45. PubMed ID: 15672299
    [Abstract] [Full Text] [Related]

  • 2. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [Abstract] [Full Text] [Related]

  • 3. Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation secondary to age-related macular degeneration.
    Voelker M, Gelisken F, Ziemssen F, Wachtlin J, Grisanti S.
    Graefes Arch Clin Exp Ophthalmol; 2005 Dec; 243(12):1241-6. PubMed ID: 16010552
    [Abstract] [Full Text] [Related]

  • 4. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
    Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.
    Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980
    [Abstract] [Full Text] [Related]

  • 5. Photodynamic therapy in practice: a review of the results of the first 12 months experience with verteporfin at the Royal Victorian Eye and Ear Hospital.
    Essex RW, Qureshi SH, Cain MS, Harper CA, Guymer RH.
    Clin Exp Ophthalmol; 2003 Dec; 31(6):476-81. PubMed ID: 14641153
    [Abstract] [Full Text] [Related]

  • 6. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.
    Augustin AJ, Schmidt-Erfurth U.
    Ophthalmology; 2006 Jan; 113(1):14-22. PubMed ID: 16360209
    [Abstract] [Full Text] [Related]

  • 7. Photodynamic therapy with verteporfin for choroidal neovascularization due to age-related macular degeneration and other causes: a New Zealand outcomes study.
    Sharp DM, Lai S, Markey CM.
    Clin Exp Ophthalmol; 2007 Jan; 35(1):24-31. PubMed ID: 17300567
    [Abstract] [Full Text] [Related]

  • 8. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
    Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB, Manos K, Hao Y, Hayes L, Koester J, Reaves A, Strong HA, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.
    Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
    Costa RA, Jorge R, Calucci D, Melo LA, Cardillo JA, Scott IU.
    Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.
    Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Monés JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.
    Arch Ophthalmol; 2002 Oct; 120(10):1307-14. PubMed ID: 12365909
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Encouraging results of photodynamic therapy with Visudyne in a clinical patient material of age-related macular degeneration.
    Frennesson CI, Nilsson SE.
    Acta Ophthalmol Scand; 2004 Dec; 82(6):645-50. PubMed ID: 15606458
    [Abstract] [Full Text] [Related]

  • 18. [Photodynamic therapy with verteporfin for recurrent choroidal neovascularisation (CNV) following prior argon laser coagulation].
    Gabel-Pfisterer A, Wehner A, Heimann H, Foerster MH, Wachtlin J.
    Ophthalmologe; 2005 Jun; 102(6):592-6. PubMed ID: 15662503
    [Abstract] [Full Text] [Related]

  • 19. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.
    Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane AM, Birngruber R, van den Berg H, Strong A, Manjuris U, Gray T, Fsadni M, Bressler NM, Gragoudas ES.
    Arch Ophthalmol; 1999 Sep; 117(9):1161-73. PubMed ID: 10496388
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.